Summary of findings 1. Summary of findings.

Participants/Populations: immunocompromised people at risk for invasive fungal infections
Prior testing: none
Settings: hospital setting
Index test: commercially available serum BDG test
Importance: test needed to accurately detect fungal infections in susceptible people at an early enough stage to facilitate antifungal treatment
Reference standard: EORTC/MSG criteria, or by microscopy or autopsy
Studies: 49 studies with 6244 participants
1. Test assay
Test/Subgroup	No. of participants (studies)	Overall sensitivity (range)	Overall specificity (range)	Implications	Quality and comments
Fungitell	4316 (36)	27% to 100%	0 to 100%	Wide variation in sensitivity and specificity. Summary estimates would not be meaningful
Glucatell	957 (5)	50% to 92%	41% to 94%	Wide variation in sensitivity and specificity. Summary estimates would not be meaningful
Wako	420 (3)	50% to 86%	89% to 100%		Insufficient number of studies for meta‐analysis
Fungitec‐G	353 (3)	67% to 88%	60% to 85%		Too few studies for meta‐analysis
Dynamiker Fungus	198 (2)	64% to 81%	78% to 80%		Too few studies for meta‐analysis
2. Fungal organism
Test/Subgroup	No. of participants (studies)	Sensitivity estimate (95% CI)	Specificity estimate (95% CI)	Implications	Quality and comments
Candida	1185 (10)	81% (75% to 86%)	64% (56% to 72%)	Results are more homogeneous for Candida testing than for all fungi

BDG: beta‐D‐glucan test; CI: confidence interval; EORTC/MSG: European Organization for Research and Treatment of Cancer Mycoses Study Group.